Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (June 2023)
33 slides from Cantargia Ab's investor presentation, June 2023
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation June 2023 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Strategy to improve current cancer therapies
Cantargia – Strategy to improve current cancer therapies IL1RAP – A NOVEL TARGET WITH SEVERAL OPPORTUNITIES; CURRENT FOCUS ON SYNERGISTIC COMBINATIONS MDSC – Myeloid-Derived Suppressor Cells 3
Slide 4: New strategy to treat cancer supported by clinical results
New strategy to treat cancer supported by clinical results PROMISING DATA IN PANCREATIC CANCER → Stronger efficacy than expected from chemotherapy alone → Patients with higher IL1RAP level benefit more Nadunolimab Durable response 50% Primary Chemo- Short-term Best change in tumor size tumor therapy
Slide 5: IL1RAP – Broad application in cancer and autoimmune disease
IL1RAP – Broad application in cancer and autoimmune disease 5
Slide 6: Nadunolimab (CAN04) Overview
NADUNOLIMAB (CAN04) OVERVIEW
Slide 7: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT 100% IL1RAP-expressing tumors 75% 50% 25% 0% l C C st al ic er er ta SC CL at ge ea Liv d ec ad re NS HN ha Br r nc lo Bl op Co Pa Es Cancer
Slide 8: Targeting IL1RAP provides unique opportunities to treat cancer by IL-1α/β blockade and ADCC
Targeting IL1RAP provides unique opportunities to treat cancer by IL-1α/β blockade and ADCC Nadunolimab NADUNOLIMAB COUNTERACTS IMMUNE SUPPRESSION AND POTENTIATES THERAPY ADCC – Antibody-Dependent Cellular Cytotoxicity; NK – Natural Killer; TIR – Toll-Interleukin-1 Receptor 8
Slide 9: Nadunolimab potentiates antitumor activity of chemotherapy
Nadunolimab potentiates antitumor activity of chemo- therapy Nadunolimab IL-1α Tumor growth * 20 100 Relative expression Tumor volume (%) 15 ** Control Docetaxel 10 50 Anti-IL-1β + Docetaxel Nadunolimab + Docetaxel 5 0 0 4 500 Docetaxel (nM) → Nadunolimab blocks both IL-1α and → Docetaxel induces IL
Slide 10: Chemotherapy induces IL-1α and IL-1β in the tumor
Chemotherapy induces IL-1α and IL-1β in the tumor IL-1α IL-1β-converting enzyme Tumor cell region (T) Stromal cell region (S) 6 * Control Gem/Cis 250 ** Control Gem/Cis 2 Positive cells/mm % Positive cells S 200 T T 4 T 150 S S 100 2 S T T 50 T 0 0 l s t ro Ci is l / ro n /C Co Gem nt m Co Ge → Gem/
Slide 11: Targeting IL1RAP uniquely synergizes with chemotherapy
Targeting IL1RAP uniquely synergizes with chemotherapy Tumor growth Body weight 2000 0 Tumor volume (mm ) 3 1500 Vehicle % Change Iso Control -5 Vehicle 1000 Nadunolimab Gem/Cis Gem/Cis ** Nadunolimab+Gem/Cis Nadunolimab+Gem/Cis -10 500 * 0 -15 0 5 10 15 Day post-treatment → Nadunolimab increases ef
Slide 12: Nadunolimab (CAN04) Clinical Results
NADUNOLIMAB (CAN04) CLINICAL RESULTS
Slide 13: NSCLC – Induction of IL1RAP and IL-1α with therapy
NSCLC – Induction of IL1RAP and IL-1α with therapy Pre-treatment On treatment (Nadunolimab + Gem/Cis) IL1RAP (brown) IL-1α (brown) IL-1α INDUCED BY CHEMOTHERAPY IN LINE WITH PRECLINICAL FINDINGS; WELL ESTABLISHED DANGER SIGNAL – ACTIVITY BLOCKED BY NADUNOLIMAB 13
Slide 14: PDAC – Staging and treatment
PDAC – Staging and treatment Expected number of cases US 2023: 64,000 Stage I - local: 3,200 Stage II - regional LN; 3,200 Stage IV - Stage III - metastatic: locally adv: 32,000 25,600 Stage I Stage II Stage III Stage IV RESECTABLE OR BORDERLINE RESECTABLE DISEASE LOCALLY ADVANCED OR METASTATIC DISE
Slide 15: PDAC – Positive interim data in 1st line patients
PDAC – Positive interim data in 1st line patients Best responses according to iRECIST OS and iPFS for mITT patients Nadunolimab combination 50% Best change in tumor size with Gem/Abraxane in 1st line PDAC (n=73): 0% → 33% response rate with long PFS and OS -50% → Additional 5 (7%) patients had on-tr
Slide 16: PDAC – Strong efficacy in patients with high tumor IL1RAP level
PDAC – Strong efficacy in patients with high tumor IL1RAP level IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% Efficacy analysis for IL1RAP High (n=27) vs IL1RAP Low (n=19) PDAC patients: → Significantly prolonged OS in ILRAP High vs IL1RAP Low patients (14.2 vs
Slide 17: PDAC – Patients with high tumor IL1RAP level have the strongest benefit
PDAC – Patients with high tumor IL1RAP level have the OS Nadunolimab/GN IL1RAP High Nadunolimab monotherapy strongest benefit of nadunolimab combination therapy OS Death On study Nadunolimab/GN iUPD/iCPD IL1RAP High Nadunolimab monotherapy iSD Death iPR Treatment cour
Slide 18: PDAC – Safety profile is manageable and supports MOA
PDAC – Safety profile is manageable and supports MOA → Neutropenia manageable through G-CSF prophylaxis → In 7 patients given G-CSF prophylaxis, only 1 developed grade 3-4 neutropenia All Patients in All Cycles → Only 1 % peripheral neuropathy grade 3-4 observed (17% in historical controls) 100% n=6
Slide 19: PDAC – Phase IIb study design
PDAC – Phase IIb study design Open-label, randomized, controlled, non-comparative, 3-arm study evaluating 2 dose levels of nadunolimab + gemcitabine/nab-paclitaxel with gemcitabine/nab-paclitaxel as control: Analysis Groups Timelines: All → Regulatory submission H2 2023 → FPI early 2024; top-line re
Slide 20: NSCLC – Promising efficacy of nadunolimab combination therapy
NSCLC – Promising efficacy of nadunolimab combination therapy OS and PFS for mITT patients PFS by dose level Nadunolimab combination with Gem/Cis in 1st/2nd line NSCLC (n=30): → ORR 53%, 13.7 mo median OS, 7.0 mo median PFS (dose-response trend for PFS) → Generally well tolerated; neutropenia freque
Slide 21: NSCLC – Promising efficacy of nadunolimab combination therapy
NSCLC – Promising efficacy of nadunolimab combination therapy Best responses according to RECIST 50% Best change in tumor size 0% High ORR to nadunolimab and platinum 1L/2L NCG doublets in different lines of therapy: 1L/2L NCP → Gem/Cis 1st/2nd line: ORR 53% (n=30) ≥3L NCG -50% → Carbo/Pemtrex 1st/2
Slide 22: NSCLC – Long-term benefit with strong signal in non-squamous subtype
NSCLC – Long-term benefit with strong signal in non- squamous subtype Non- Treatment course for each individual patient All Historical Non-squamous squamous, (n=30) data1,2 (n=16) CR1 historical data3 Median OS 13.7 mo 10.3 mo 15.9 mo 11.3 mo CR2 Median PFS 7.0 mo 5.1 mo 7.3 mo 4.9 mo OS ORR 5
Slide 23: NSCLC – Complete responders with distinct biomarker profile
NSCLC – Complete responders with distinct biomarker profile 150 Target lesion diameter Nadunolimab monotherapy NCG 100 CR (mm) 50 two lymph nodes reduced to ≤5 mm 0 0 12 24 36 48 Months 100 3 80 Positive cells (%) 60 → One CR maintained over 3 yrs (CR1), second CR Score (0-3) 40 2 PD-L1 (tumor cel
Slide 24: TNBC – Promising early safety and efficacy
TNBC – Promising early safety and efficacy Best responses according to RECIST Nadunolimab combination with Gem/Carbo in 100 % 1st/2nd line metastatic TNBC: Best change in tumor size 15 patients enrolled in the dose-escalation phase 50 % PD → Acceptable safety profile (G-CSF given prophylactically to
Slide 25: Key messages
Key messages → Most chemotherapies induce chemoresistance already after Resistant a few months of therapy. Chemotherapy can upregulate tumor both IL-1α and IL-1β. Chemo- therapy → Unlike other IL-1 blocking compounds, nadunolimab blocks both IL-1α and IL-1β signalling and improves chemotherapy effic
Slide 26: CAN10 – Opportunity in Autoimmune/Inflammatory Disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 27: CAN10 – New asset within autoimmunity/inflammation
CAN10 – New asset within autoimmunity/inflammation → IL1RAP-binding antibody potently blocking IL-1, IL-33 and IL-36, without ADCC → Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation) → Development focusing on systemic scle
Slide 28: CAN10 – Promising effects in several preclinical disease models
CAN10 – Promising effects in several preclinical disease models Viral myocarditis Disease severity Autoimmune myocarditis Cardiac function 4 *** 1.1 Ratio to baseline * ** 3 1.0 * mCAN10 Ctrl mCAN10 Score 2 0.9 Anti-IL-1β Ctrl Anti-IL-1β Vehicle 1 0.8 0 0.7 0 10 20 30 40 cle A l 0 ro 1R N1 Day nt hi
Slide 29: CAN10 – Project status
CAN10 – Project status GLP toxicity study – Completed → CAN10 given i.v. once weekly for six weeks at doses up to 50 mg/kg or s.c. at 5 mg/kg → No adverse findings related to CAN10 at/above clinically relevant (pharmacologically active) dose levels Clinical Phase I study – Study start planned for mi
Slide 30: Milestones, Financials & Summary
MILESTONES, FINANCIALS & SUMMARY
Slide 31: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC NSCLC TNBC CAN10 milestones • Start Phase IIb trial in • Presented updated • Randomized Phase II • Treatment of first • New clinical data 150-200 patients with efficacy and (TRIFOUR) – interim subject in Phase I presented from submission in H2 2023 bio
Slide 32: Solid financial position with strong shareholder support
Solid financial position with strong shareholder support → Cash and cash equivalents 353M SEK (~$33M) at end of Q1 2023 Current owners (Mar 31, 2023) → Runway until mid-2024 4th AP fund 8.8% Alecta 7.3% → Market cap appr 0.8B SEK, 75M USD May 26, 2023 1st AP fund 6.3% Avanza Pension 5.1% Six Sis AG
Slide 33: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO ADDRESS CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • Potential to break down resistance to cancer treatment, enabled by unique dual action approach – nadunolimab (CAN04) • Additional key targ